Journal: Cancers
Article Title: Discoidin Domain Receptor 2 Contributes to Breast Cancer Progression and Chemoresistance by Interacting with Collagen Type I
doi: 10.3390/cancers16244285
Figure Lengend Snippet: The effect of DDR2 on the resistance to epirubicin in the breast cancer cell lines. ( A – C ): viability of MCF-7 ( A ), MDA-MB-231 ( B ), and T47D ( C ) transfected with an empty vector or DDR2-expressing vector under epirubicin treatment (500 nM for MCF-7; 250 nM for MDA-MB-231 and T47D). These cells were plated onto collagen-coated culture plates. * p < 0.05, ** p < 0.01, and *** p < 0.001 compared to the empty vector, respectively. ( D – F ): viability of MCF-7 ( D ), MDA-MB-231 ( E ), and T47D ( F ) transfected with siRNA targeting DDR2 under epirubicin treatment. ( G , H ) mRNA and protein expression in chemosensitive parental cells and epirubicin-resistant cells ( G ; MCF-7 series, H ; MDA-MB-231 series). ** p < 0.01, respectively. ( I , J ) The effect of DDR2 inhibitor WRG-28 treatment (48 h) on the proliferation of chemosensitive parental cells and epirubicin-resistant cells ( F ; MCF-7 series, G ; MDA-MB-231 series).
Article Snippet: The rabbit polyclonal antibody against DDR2 was purchased from GeneTex (Irvine, CA, USA).
Techniques: Transfection, Plasmid Preparation, Expressing